Synaptogenix Inc (SNPX)

[Cyosol]

They certainly have more potent drugs in development, but since that's all pre-clinical stuff I wouldn't really worry about that until the late 2020s (unless of course a partnership or acquisition significantly fills up their coffers with more cash).

Even Bryostatin will mostly likely need a phase 3 going into the early 2020s before it starts bringing in any revenue.

For investors, I think a more relevant focus for now will be on how big pharma and the rest of the world reacts after the next results are released.